Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2008 | Short Communication

Initial evaluation of ¹⁸F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Authors: A. Quon, S. T. Chang, F. Chin, A. Kamaya, D. W. Dick, B. W. Loo Jr., S. S. Gambhir, A. C. Koong

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2008

Abstract

Purpose

The aim of this study was to evaluate the potential of ¹⁸F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma.

Methods

This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, ¹⁸F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses.

Results

The primary tumor size ranged from 2.5×2.8 cm to 3.5 × 7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%).

Conclusions

In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.

Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med Sep. 2003;44(9):1432–4.PubMed

Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med Sep. 2003;44(9):1426–31.

Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Cancer Res 2007;13(12):3552–8.PubMedCrossRef

Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8(1):36–42.PubMedCrossRef

Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [(18)F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007;34(6):878–83.PubMedCrossRef

Seitz U, Wagner M, Neumaier B, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;29(9):1174–81.PubMedCrossRef

Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243(3):843–6.CrossRef

Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32(4):623–48; discussion 649–650.PubMed

Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in “clinical reality”. Ann Nucl Med 2003;17(4):261–79.PubMedCrossRef

10.

van Kouwen MC, Jansen JB, van Goor H, de Castro S, Oyen WJ, Drenth JP. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Ann Nucl Med 2005;32(4):399–404.

11.

Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1 regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69–89.PubMedCrossRef

12.

Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32(3):257–63.PubMedCrossRef

13.

Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biology 2004;31(7):829–37.CrossRef

Title: Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer
Authors: A. Quon
S. T. Chang
F. Chin
A. Kamaya
D. W. Dick
B. W. Loo Jr.
S. S. Gambhir
A. C. Koong
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0630-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Initial evaluation of ¹⁸F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

Society communication

Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?

FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries

EANM-ESR white paper on multimodality imaging

99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy

99mTc-sestamibi kinetics predict myocardial viability in a perfused rat heart model